Table 3 Clinical trials of CD3+ bispecific T-cell redirectors for solid cancers.
From: Overcoming the challenges associated with CD3+ T-cell redirection in cancer
Targets | Clinical trial Phase | Clinical trial identifier | Disease indication(s) | Organisation(s) | Antibody |
|---|---|---|---|---|---|
CD3 × B7-H3 | Phase 1 | NCT03406949 | Advanced solid tumours | MacroGenics | Orlotamab; MGD009 |
CD3 × CEACAM | Phase 1 | NCT02291614 NCT01284231 NCT02760199 | Gastrointestinal adenocarcinoma | Amgen; MedImmune | AMG 211; MEDI-565 |
CD3 × CEACAM | Phase 1/2 | NCT03866239 NCT03337698 NCT02650713 NCT02324257 | Colorectal cancer; NSCLC | Hoffmann-La Roche | Cibisatamab; RO6958688 |
CD3 × CLDN18.2 | Phase 1 | NCT04260191 | Gastric and gastro-oesophageal junction adenocarcinoma | Amgen | AMG 910 |
CD3 × DLL3 | Phase 1 | NCT03319940 | SCLC | Amgen | AMG 757 |
CD3 × EGFRvIII | Phase 1 | NCT03296696 | Glioblastoma | Amgen | AMG 596 |
CD3 × EGFR | Phase 1/2 | NCT01420874 NCT02620865 NCT03269526 NCT03344250 | Pancreatic cancer; colorectal cancer; glioblastoma | Barbara Ann Karmanos Cancer Institute; University of Virginia | EGFR2Bi-ATC; EGFR-BATs |
CD3 × EpCAM | Phase 1 | CTR20181212 | Malignant ascites | Wuhan YZY Biopharma | M701 |
CD3 × EpCAM | Withdrawn from market | Withdrawn from market | Malignant ascites | Trion Pharma | Catumaxomab; Removab |
CD3 × GD2 | Phase 1/2 | NCT02173093 | Neuroblastoma | University of Virginia | GD2Bi-aATC |
CD3 × gpA33 | Phase 1/2 | NCT03531632 NCT02248805 | Colorectal cancer | MacroGenics | MGD007 |
CD3 × gp100 | Phase 1/2 | NCT03070392 NCT02535078 NCT02570308 NCT01211262 NCT01209676 | Uveal melanoma; malignant melanoma | Immunocore; University of Pennsylvania | IMCgp100 |
CD3 × GPC3 | Phase 1 | NCT02748837 | Solid tumours | Chugai Pharmaceutical | ERY974 |
CD3 × GUCY2c | Phase 1 | NCT04171141 | Gastrointestinal tumours; colorectal cancer; oesophageal adenocarcinomas | Pfizer | PF-07062119 |
CD3 × HER2 | Phase 1/2 | NCT03406858 NCT03661424 NCT03272334 NCT00027807 | Prostate cancer; breast cancer; leptomeningeal metastases | Barbara Ann Karmanos Cancer Institute; University of Virginia | HER2Bi-ATC; HER2-BATs |
CD3 × HER2 | Phase 1 | NCT03448042 | Solid tumours | Genentech | BTRC4017A |
CD3 × HER2 | Phase 1/2 | NCT03983395 | Breast cancer | Glenmark Pharmaceuticals | GBR 1302; ISB 1302 |
CD3 × HER2 | Phase 1 | CTR20171194 | Advanced solid tumours | Wuhan YZY Biopharma | M802 |
CD3 × MAGE-A4 | Phase 1/2 | NCT03973333 | Advanced solid tumours | Immunocore Ltd | IMC-C103C |
CD3 × MSLN × ALB | Phase 1/2 | NCT03872206 | Ovarian cancer; fallopian tube cancer; peritoneal cancer; pancreatic cancer; mesothelioma | Harpoon Therapeutics | HPN536 |
CD3 × MUC1 | Phase 2 | NCT03540199 NCT03524261 NCT03501056 NCT03554395 NCT03509298 NCT03524274 NCT03484962 NCT03146637 | Kidney cancer; breast cancer; lung cancer; gastric cancer; pancreatic cancer; colorectal cancer; liver cancer | Fuda Cancer Hospital, Guangzhou; Benhealth Biopharmaceutical | Activated CIK and CD3-MUC1 |
CD3 × MUC16 | Phase 1/2 | NCT03564340 | Ovarian cancer; fallopian tube cancer; primary peritoneal cancer | Regeneron; Sanofi | REGN4018 |
CD3 × MUC17 | Phase 1 | NCT04117958 | Gastric and gastro-oesophageal junction cancer | Amgen | AMG 199 |
CD3 × P-cadherin | Phase 1 | NCT02659631 | Triple-negative breast cancer; colorectal cancer; NSCLC | Pfizer | PF-06671008 |
CD3 × PRAME | Phase 1/2 | NCT04262466 | Advanced solid tumours | Immunocore Ltd | IMC-F106C |
CD3 × PSCA | Phase 1 | NCT03927573 | Pancreatic cancer; breast cancer; urogenital cancer; NSCLC | Celgene | GEM3PSCA |
CD3 × PSMA | Phase 1 | NCT03926013 | Prostate cancer; renal cell carcinoma | Janssen | JNJ-63898081 |
CD3 × PSMA | Phase 1 | NCT03792841 | Prostate cancer | Amgen | AMG 160 |
CD3 × PSMA | Phase 1 | NCT01723475 | Prostate cancer | Amgen; Bayer | Pasotuxizumab; AMG 212 |
CD3 × PSMA | Phase 1 | NCT02262910 | Prostate cancer | Aptevo Therapeutics | ES414 |
CD3 × PSMA × ALB | Phase 1 | NCT03577028 | Prostate cancer | Harpoon Therapeutics | HPN424 |
CD3 × SSTR2 | Phase 1 | NCT03411915 | Neuroendocrine tumours; gastrointestinal stromal tumours | Xencor | Tidutamab; XmAb18087 |
CD3 × STEAP1 | Phase 1 | NCT04221542 | Prostate cancer | Amgen | AMG 509 |
CD3 × 5T4 | Phase 1/2 | NCT04424641 | Solid tumours | Genmab; AbbVie | GEN1044 |
